Table 2 Baseline characteristics by adequate (>10%) systolic blood pressure response to spironolactone
SBP response | |||
|---|---|---|---|
Variable | >10% | ⩽10% | P-value |
n | 17 | 31 | |
Sex (male)—n, % | 12 (70.6) | 14 (45.2) | 0.286 |
Age (years)—mean (s.d.) | 65.2 (13.1) | 65.5 (9.9) | 0.926 |
BMI (kg m−2)—mean (s.d.) | 29.1 (4.9) | 27.9 (4.9) | 0.445 |
Pre-spironolactone BP—mean (s.d.) | |||
Systolic BP, mm Hg | 168 (25) | 150 (19) | 0.006 |
Diastolic BP, mm Hg | 92 (25) | 82 (12) | 0.152 |
Comorbidities—n (%) | |||
Diabetes | 7 (41.2) | 9 (29.0) | 0.393 |
Hyperlipidemia | 1 (5.9) | 0 (0.0) | 0.172 |
Ischemic heart disease | 2 (11.8) | 9 (29.0) | 0.173 |
Cerebral vascular disease | 0 (0.0) | 0 (0.0) | — |
Smoking | 1 (5.9) | 2 (6.5) | 0.938 |
Antihypertensive drugs—median (s.d.) | 3.5 (1.0) | 4.0 (1.0) | 0.205 |
Antihypertensive drugs—n (%) | |||
Beta blocker | 12 (70.6) | 28 (90.3) | 0.079 |
Calcium channel blocker | 14 (82.4) | 27 (87.1) | 0.656 |
ACE inhibitor/AR blocker | 13 (76.5) | 29 (93.5) | 0.087 |
Diuretic | 15 (88.2) | 29 (93.5) | 0.524 |
Alpha blocker | 5 (29.4) | 5 (16.1) | 0.278 |
Laboratory values—median (s.d.) | |||
Sodium, mEq l−1 | 140 (3.0) | 140 (3.6) | 0.786 |
Potassium, mEq l−1 | 3.95 (0.6) | 4.55 (0.8) | 0.037 |
Creatinine, mg dl−1 | 0.98 (0.3) | 1.1 (0.2) | 0.398 |
Urea, mg dl−1 | 34 (16.8) | 41 (16.0) | 0.317 |
Target organ damage—n/tested (%) | |||
Left ventricular hypertrophy | 9/11 (81.8) | 10/16 (62.5) | 0.280 |
Microalbuminuria | 5/11 (45.5) | 3/15 (20.0) | 0.165 |
